

Publication list

**ORIGINAL ARTICLES**

1. Gossmann J, **Wilhelm A**, Kachel H. G., Jordan J, Sann U, Geiger H, Kramer W, Scheuermann EH  
Long-term consequences of live kidney donation follow-up in 93% of living kidney donors in a single transplant center  
*Am J Transplant.* 2005;5(10):2417-24
2. Hamscho N, **Wilhelm A**, Döbert N, Menzel C, Gossmann J, Berner U, Zaplatnikov K, Scheuermann EH, Grünwald F  
Residual kidney function after donor nephrectomy. Assessment by 99mTc-MAG3-clearance  
*Nuklearmedizin.* 2005;44(5):200-4
3. Jordan J, Sann U, Janton A, Gossmann J, Kramer W, Kachel HG, **Wilhelm A**, Scheuermann EH  
Living kidney donors' long-term psychological status and health behavior after nephrectomy - a retrospective study  
*J Nephrol.* 2004;17(5):728-35
4. Hofmann L, Simon-Zoula S, **Nowak A**, Giger A, Vock P, Boesch C, Frey F, Vogt B.  
BOLD-MRI for the assessment of renal oxygenation in humans: Acute effect of nephrotoxic xenobiotics  
*Kidney Int.* 70(1):144-50
5. Sollinger D, Mohaupt MG, **Wilhelm A**, Uehlinger D, Frey FJ, Eisenberger U  
Arterial stiffness assessed by digital volume pulse correlates with comorbidity in patients with ESRD  
*Am J Kidney Dis.* 2006;48(3):456-63
6. Breidhardt T, Socrates T, Noveanu M, Klima T, Heinisch C, Reichlin T, Potocki M, **Nowak A**, Tschung C, Arenja N, Bingisser R, Mueller C.  
Impact and Clinical Prediction of Worsening Renal Function in Acute Decompensated Heart Failure  
*Am J Cardiol.* 2011;107(5):730-5
7. **Nowak A**, Breidhardt T, Christ-Crain M, Bingisser R, Meune C, Tanglay Y, Heinisch C, Reiter M, Drexler B, Arenja N, Twerenbold R, Stolz D, Tamm M, Müller B, Müller C  
Direct Comparison of Three Natriuretic Peptides for Prediction of Short- and Long-term Mortality in Patients With Community-Acquired Pneumonia  
*Chest.* 2012;141(4):974-82.
8. **Nowak A**, Breidhardt T, Dejung S, Christ-Crain M, Bingisser R, Drexler B, Meune C, Marono D, Mosimann T, Müller B, Müller C

Natriuretic Peptides for early prediction of acute kidney injury in community acquired pneumonia  
*Clinica Chimica Acta*, 2013 Apr 18;419:67-72

9. Artunc F, **Nowak A**, Mueller C, Breidthardt T, Twerenbold R, Wagner R, Friedrich B  
Plasma concentrations of the vasoactive peptides mid-regional pro-adrenomedullin, copeptin and c-terminal pro-endothelin 1 in hemodialysis patients: associated factors and prediction of mortality  
*PLoS One*. 2014 Jan 22;9(1):e86148
10. Fauchère I, Moormann D, Maier W, Altweg L, Lüscher T, Grünenfelder J, **Nowak A**, Tüller D, Genoni M, Falk V, Hermann M  
Rehabilitation After TAVI Compared To Surgical Aortic Valve Replacement  
*Int J Cardiol*. 2014 May 15;173(3):564-6
11. **Nowak A**, Friedrich B, Artunc F, Serra AL, Breidthardt T, Twerenbold R, Peter M, Potocki M, Mueller C  
Prognostic value and link to atrial fibrillation of soluble Klotho and FGF23 in hemodialysis patients  
*PLoS One*. 2014 Jul 3;9(7):e100688
12. Muskalla AM, Suter PM, Saur M, **Nowak A**, Hersberger M, Krayenbuehl PA  
G-Protein Receptor Kinase 4 Polymorphism and Response to Antihypertensive Therapy  
*Clin Chem*. 2014 Dec;60(12):1543-8
13. Artunc F, **Nowak A**, Müller C, Peter A, Heyne N, Häring H-U, Friedrich B  
Mortality prediction using modern peptide biomarkers in hemodialysis patients – a comparative analysis  
*Kidney Blood Press Res*. 2014 Dec 15;39(6):563-572
14. **Nowak A**, Artunc F, Serra A, Müller C, Pollock E, Krayenbuehl P-A, Friedrich B  
Sclerostin and other circulating bone remodeling markers in hemodialysis patients  
*Kidney Blood Press Res*. 2015;40(3):266-76
15. Weidmann ZM, Breidthardt T, Twerenbold R, Züsli C, **Nowak A**, von Eckardstein A, Erne P, Rentsch K, de Oliveira MT Jr, Gualandro D, Maeder MT, Rubini Gimenez M, Pershyna K, Stallone F, Haas L, Jaeger C, Wildi K, Puelacher C, Honegger U, Wagener M, Wittmer S, Schumacher C, Krivoshei L, Hillinger P, Osswald S, Mueller C  
Prediction of mortality using quantification of renal function in acute heart failure  
*Int J Cardiol*.. 2015 Dec 15;201:650-7
16. Schmied C, **Nowak A**, Gruner C, Olinger E, Debaix H, Brauchlin A, Frank M, Reidt S, Monney P, Barbey F, Shah D, Namdar M  
The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy

*Heart*. 2016 Aug 15;102(16):1309-14

17. **Nowak A**, Mechtler TP, Desnick RJ, Kasper DC  
Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes  
*Mol Genet Metab*. 2017 Jan - Feb;120(1-2):57-61
18. **Nowak A**, Boesch L, Andres E, Battegay E, Hornemann T, Schmid C, Bischoff-Ferrari H, Suter P, Krayenbuehl P-A  
Effect of vitamin D3 on self-perceived fatigue: a double-blind randomized placebo-controlled trial.  
*Medicine*, (Baltimore). 2016 Dec;95(52):e5353
19. **Nowak A**, Koch G, Huynh-Do U, Siegenthaler M, Marti H-P, Pfister M  
Disease progression modeling to evaluate the effects of enzyme replacement therapy on kidney function in adult patients with the Classic phenotype of Fabry disease.  
*Kidney Blood Press Res*. 2017;42(1):1-15.
20. Menghini M, Prünke Ch, Krayenbuehl PA, **Nowak A**  
Assessment of drusen and other retinal degenerative changes in patients with hereditary hemochromatosis  
*Retina*. 0:1–6, 2017
21. Saleh L, Tang J, Gawinecka J, Boesch L, Fraser WD, von Eckardstein A, **Nowak A**  
Impact of a single oral dose of 100,000 IU vitamin D3 on vitamin D metabolite profiles in healthy adults with vitamin D insufficiency  
*Clin Chem Lab Med*. 2017 Mar 22 [Epub ahead of print]
22. **Nowak A**, Mechtler TP, Kasper DC, Desnick RJ  
Correlation of Lyso-Gb3 levels in Dried Blood Spots and Sera from patients with Classic and Later-Onset Fabry Disease  
*Mol Genet Metab*. 2017 Aug;121(4):320-324
23. **Nowak A**, Franzen DP, Haile SR, Mottet D, Bonani M, Kohler M, Krayenbuehl PA, Barbey F  
Long-term follow-up of pulmonary function in Fabry disease: a multi-center observational study  
*PLoS One*. 2017 Jul 25;12(7):e0180437
24. Lenders M, Oder D, **Nowak A**, Canaan-Kühl S, Arash-Kaps L, Drechsler C, Schmitz B, Nordbeck P, Hennermann JB, Kampmann C, Reuter S, Brand SM, Wanner C, Brand E.  
Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.  
*J Intern Med*. 2017 Sep;282(3):241-253
25. Siegenthaler M, U. Huynh-Do U, Krayenbuehl P, Pollock E, Widmer U, Debaix H, Olinger E, Frank M, Namdar M, Ruschitzka F, **Nowak A**

Impact of Cardio-Renal Syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up  
*Int J Cardiol.* 2017 Dec 15;249:261-267

26. Annema W, **Nowak A**, von Eckardstein A, Saleh L  
Evaluation of the new restandardized Abbott Architect 25-OH Vitamin D assay in vitamin D-insufficient and vitamin D-supplemented individuals  
*J Clin Lab Anal.* 2017 Sep 19 doi: 10.1002/jcla.22328. [Epub ahead of print]
27. **Nowak A**, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, Kasper DC  
Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease  
*Mol Genet Metab.* *Mol Genet Metab.* 2018 Feb;123(2):148-153
28. Ersözlü S, Desnick RJ, Huynh-Do U, Canaan-Kühl S, Barbey F, Genitsch V, Müller T, Cheetham M, Flammer A, Schaub S, **Nowak A**  
Long-Term Outcomes of Kidney Transplantation in Fabry Disease  
*Transplantation*, in press
29. Franzen D, Haile S, Kasper D, Mechtler P, Flammer A, Krayenbuehl PA, **Nowak A**  
Pulmonary involvement in Fabry disease: Effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy  
*BMJ Open Respir Res*, 2018 Apr 21;5(1):e000277
30. Kölling M, Seeger H, Haddad G, Kistler A, **Nowak A**, Faulhaber-Walter R, Kielstein J, Haller H, Fliser D, Mueller T, Wüthrich RP, Lorenzen JM  
The Circular RNA *ciRs-126* Predicts Survival in Critically Ill Patients With Acute Kidney Injury  
*Kidney Int Rep.* 2018 Jun 2;3(5):1144-1152
31. Lenders M, Neusser L, Rudnicki M, Nordbeck P, Canaan-Kühl S, **Nowak A**, Cybulla M, Schmitz B, Lukas J, Wanner C, Brand S-M, Brand E  
Dose-dependent impact of enzyme replacement therapy on anti-drug antibody titers and clinical outcomes in patients with Fabry disease  
*J Am Soc Nephrol*, in press
32. **Nowak A**, Giger RS, Krayenbuehl PA  
Higher age at diagnosis of Hemochromatosis is the strongest predictor of the occurrence of Hepatocellular Carcinoma in the Swiss Hemochromatosis Cohort: a prospective longitudinal observational study  
*Medicine*, in press

## REVIEW ARTICLES

1. Göksu Y, Hofbauer G, Serra AL, **Nowak A**  
Maligne Hauterkrankungen bei organtransplantierten Patienten  
*Praxis (Bern 1994).* 2012;18;101(2):75-83
2. Mayer F, Hofbauer G, **Nowak A**

Frühe kutane Karzinogenese bei organtransplantierten Patienten  
*Praxis* (Bern 1994). 2012;31;101(22):1401-9

3. **Nowak A**, Krayenbühl P.-A  
Extraskelettale Vitamin-D-Wirkungen  
*Leading Opinions* 2013/2; 8-12
4. **Nowak A**, L. Serra AL  
Abklärung der Proteinurie  
*Praxis* (Bern 1994). 2013 Jun 1;102(13):797-802
5. Hakman P, Vallelian F, **Nowak A**  
Riesenzelleritits  
*Praxis* (Bern 1994). 2013 Jun 5;102(12):703-8; quiz 709-10
6. Müggler A, Iseli SM, Meindl-Fridez C, **Nowak A**, Brunckhorst CB  
AV-Knoten-Reentry-Tachykardie  
*Praxis* (Bern 1994). 2013 Sept 1;102(19):1155-64
7. **Nowak A**, Göhner K, Cohen C  
Caplan-Syndrom: eine untypische Differentialdiagnose des „pulmo-renalen“  
Syndroms  
*Praxis* (Bern 1994). 2014 Feb 26;103(5):279-84
8. Pollock E, **Nowak A**  
The cardio-renal problem  
*Swiss Med Wkly*. 2014 Dec 4;144:w14051. doi: 10.4414/smw.2014.14051
9. Steinack C, Gaspert A, Kovacs R, **Nowak A**  
Morbus Fabry: Selten, aber nicht zu verpassen. CME  
*Praxis* (Bern 1994). 2015 Jul;104(14):719-29
10. Rodieux F, Pfister M, van den Anker J, Rohrbach M, Schuknecht B, Gaspert  
A, Palla A, **Nowak A**  
Unexplained peripheral neuropathic pain and/or unexplained stroke in young  
patients - think about Fabry disease  
*Swiss Archives of Neurology, Psychiatry and Psychotherapy* 2016  
Apr;167(3)74-80
11. Schreiner F, Krayenbühl PA, Goede J, **Nowak A**  
Approach to the Patient with Elevated Serum Ferritin  
*Praxis* (Bern 1994). 2016 May 11;105(10):543-51
12. **Nowak A**  
Linksherzhypertrophie – denken Sie an einen Morbus Fabry  
*Cardiovascular Medicine*. 2016;19(05)
13. Krüger S, **Nowak A**, Lang K, Müller TC  
Case report on General anesthesia and Fabry disease  
*A A Case Rep*. 2017 May 15;8(10):247-249

14. Battegay E, Cheetham M, Holzer BM, **Nowak A**, Schmidt D, Rampini S  
Multimorbiditätsmanagement im Alltagsdilemma  
*Der Internist*. 2017 DOI 10.1007/s00108-017-0200-9
15. Lüthi L, Andreas Kistler A, **Nowak A**  
Hyperkaliämie bei Patienten mit chronischer Hämodialyse (exotische Ursache, lebensbedrohliche Folge)  
*Praxis (Bern 1994)*. 2017 Jun;106(12):679
16. Lecheler L, Richter M, Franzen DP, Rampini SK, Cheetham M, Jenewein J, Battegay E, **Nowak A**  
The frequent and underrecognized co-occurrence of Acute Exacerbated Chronic Obstructive Pulmonary Disease and Depression warrants screening: a systematic review  
*Eur Respir Rev*. 2017 Jun 14;26(144)
17. Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, **Nowak A**, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ.  
European expert consensus statement on therapeutic goals in Fabry disease.  
*Mol Genet Metab*. 2018 Jul;124(3):189-203.
18. Müller S, Tanner F, Gruner C, Ruschitzka F, Flammer A, **Nowak A**  
*Morbus Fabry - Eine seltene, aber wichtige Ursache einer Linksventrikulären Hypertrophie*  
*Cardiovascular Medicine, in press*
19. Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, **Nowak A**, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ  
European expert consensus statement on therapeutic goals in Fabry disease.  
*Mol Genet Metab*. 2018 Jul;124(3):189-203
20. Tamo R, Rohrbach M, Baumgartner M, Beuschlein F, Nowak A  
The basics of lysosomal storage diseases  
*Ther Umsch*, in press
21. Tamo R, Hochuli M, Beuschlein F, **Nowak A**  
Morbus Gaucher – ein Überblick über eine Sphingolipidose  
*Ther Umsch*, in press
22. Tamo R, Zweifel S, Beuschlein F, **Nowak A**  
Morbus Fabry – das Porträt einer seltenen Erkrankung  
*Ther Umsch*, in press

## BOOKS

Frederique Barbey, **Albina Nowak**

Die Fabry Krankheit erklären. Von Ärzten für Kinder Verpasst! Medikidz 14 Basil Street, London 2017.

## LETTERS

1. Nowak A, Siegenthaler M, Namdar M, Ruschitzka F  
Reply: Impact of Cardio-Renal Syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up.  
*Int J Cardiol.* 2018 May 1;258:206